|
Peripheral natural killer cells are a prognostic factor in advanced oesogastric adenocarcinoma and are associated with intestinal types in the randomized trial PRODIGE17-ACCORD20 (UNICANCER GI). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Merck; Sanofi |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Merck Serono; Roche; Teva |
Speakers' Bureau - Amgen; Hospira; Lilly; Novartis |
Research Funding - Pierre Fabre |
|
|
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche |
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Bayer; Lilly; Roche |
|
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
Honoraria - Amgen; Lilly; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Lilly; Roche; Sanofi |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; Roche |
|
|
|
Honoraria - Bayer; Sanofi |
Consulting or Advisory Role - Amgen; Celgene; Lilly; Merck Serono; Roche |
Travel, Accommodations, Expenses - Celgene; Merck Serono |
|
|
Consulting or Advisory Role - Bayer; Lilly; Roche |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Merck; Roche |